Topics

LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study

06:58 EDT 28 Oct 2019 | Pharmaceutical Business Review

Phase 1 study results showed escalating doses of TBC-1002 to be well tolerated with no dose limiting toxicity and no irritative voiding (cystitis) symptoms. No systemic exposure or

The post LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study appeared first on Pharmaceutical Business review.

Original Article: LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study

NEXT ARTICLE

More From BioPortfolio on "LIPAC Oncology announces successful completion of phase 1 bladder cancer clinical study and initiation of phase 2A study"

Quick Search